Published in Exp Neurol on December 11, 2009
cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. Int J Alzheimers Dis (2010) 0.84
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A (2006) 19.60
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem (1999) 6.44
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature (1996) 5.50
Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med (2001) 5.06
Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain (1996) 4.61
The skeletal muscle chloride channel in dominant and recessive human myotonia. Science (1992) 4.28
Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet (2001) 4.28
Impact of the agr quorum-sensing system on adherence to polystyrene in Staphylococcus aureus. J Infect Dis (2000) 4.19
Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet (1999) 4.02
Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol (2000) 3.99
The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging (1997) 3.94
Algorithm for neuropathic pain treatment: an evidence based proposal. Pain (2005) 3.92
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Prion dementia without characteristic pathology. Lancet (1990) 3.66
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 3.58
Extrapyramidal signs in dementia of Alzheimer type. Lancet (1989) 3.52
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology (1999) 3.49
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49
Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol (2001) 3.43
Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. Brain (2008) 3.36
Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage (2004) 3.25
House dust mite exposure as a cause of asthma. Clin Exp Allergy (1992) 3.10
Correlation between rates of brain atrophy and cognitive decline in AD. Neurology (1999) 3.07
The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry (2003) 2.97
Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol (1999) 2.92
Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet (1996) 2.89
Incident lacunes influence cognitive decline: the LADIS study. Neurology (2011) 2.81
The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology (2005) 2.77
Risk factors for asthma in inner city children. J Pediatr (1992) 2.72
The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob Agents Chemother (2000) 2.71
Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology (2007) 2.61
Sensitization and exposure to indoor allergens as risk factors for asthma among patients presenting to hospital. Am Rev Respir Dis (1993) 2.59
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology (2009) 2.58
Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed (1997) 2.56
Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl (2000) 2.56
A two-site monoclonal antibody ELISA for the quantification of the major Dermatophagoides spp. allergens, Der p I and Der f I. J Immunol Methods (1989) 2.56
Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol (1997) 2.48
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol (2007) 2.47
Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology (2008) 2.41
Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry (2002) 2.41
Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol (1998) 2.35
APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry (2011) 2.31
Subunit structure of the galactose and N-acetyl-D-galactosamine-inhibitable adherence lectin of Entamoeba histolytica. J Biol Chem (1989) 2.30
Prevalence and severity of microbleeds in a memory clinic setting. Neurology (2006) 2.29
Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology (2012) 2.23
EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol (2010) 2.21
Modeling brain deformations in Alzheimer disease by fluid registration of serial 3D MR images. J Comput Assist Tomogr (1998) 2.20
Cockroach allergens and asthma. J Allergy Clin Immunol (2001) 2.20
Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol (2004) 2.19
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 2.17
Mite faeces are a major source of house dust allergens. Nature (1981) 2.16
Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology (2001) 2.09
Comparison of 7.0-T T₂*-magnetic resonance imaging of cerebral bleeds in post-mortem brain sections of Alzheimer patients with their neuropathological correlates. Cerebrovasc Dis (2011) 2.05
Predisposing locus for Alzheimer's disease on chromosome 21. Lancet (1989) 1.99
Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry (2000) 1.97
The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy (2008) 1.96
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology (2001) 1.95
Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology (2009) 1.95
Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. AJNR Am J Neuroradiol (2001) 1.94
Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet (1996) 1.91
Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. Eur J Neurol (2000) 1.89
Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology (2009) 1.88
Quantitative assessment of exposure to dog (Can f 1) and cat (Fel d 1) allergens: relation to sensitization and asthma among children living in Los Alamos, New Mexico. J Allergy Clin Immunol (1995) 1.88
The heritability and genetics of frontotemporal lobar degeneration. Neurology (2009) 1.86
Brain activation during human navigation: gender-different neural networks as substrate of performance. Nat Neurosci (2000) 1.86
Airborne cat allergen (Fel d I). Environmental control with the cat in situ. Am Rev Respir Dis (1991) 1.85
High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry (2012) 1.84
Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain (2008) 1.84
CT and MRI rating of white matter lesions. Cerebrovasc Dis (2002) 1.83
Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.81
Monoclonal antibodies directed against the galactose-binding lectin of Entamoeba histolytica enhance adherence. J Immunol (1990) 1.79
Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke (2003) 1.78
Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J (Clin Res Ed) (1984) 1.78
CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology (2010) 1.77
Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neurosci Lett (2000) 1.77
Dust mites: immunology, allergic disease, and environmental control. J Allergy Clin Immunol (1987) 1.76
Familial aggregation in frontotemporal dementia. Neurology (1998) 1.76
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
Proposal for a histopathological consensus classification of the periprosthetic interface membrane. J Clin Pathol (2006) 1.75
Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology (2005) 1.73
The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia. J Neurol Neurosurg Psychiatry (2004) 1.73